Spots Global Cancer Trial Database for brca2 mutation

Every month we try and update this database with for brca2 mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer	NCT04651920	Epithelial Ovar... Chinese Homologous Reco... BRCA1 Mutation BRCA2 Mutation Prognosis Homologous Reco...	Evaluation of h...	18 Years -	Peking Union Medical College Hospital
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer	NCT03685331	Metastatic Brea... Locally Advance... Advanced Breast... BRCA2 Mutation BRCA1 Mutation	Palbociclib Olaparib Fulvestrant	18 Years -	Abramson Cancer Center at Penn Medicine
Depression and Body Image Distress Following Mastectomy With Reconstruction	NCT03428399	Breast Cancer BRCA1 Mutation BRCA2 Mutation	Psychosocial va...	18 Years -	Massachusetts General Hospital
Combination Therapy in Cancers With Mutations in DNA Repair Genes	NCT05694715	Metastatic Soli... BRCA1 Mutation BRCA2 Mutation ATM Gene Mutati... PALB2 Gene Muta...	Niraparib Irinotecan	18 Years -	University of California, San Francisco
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations	NCT05498272	Prostate Cancer BRCA1 Mutation BRCA2 Mutation Prostatic Adeno... High-Risk Cance...	Olaparib LHRH agonist	18 Years -	Hoosier Cancer Research Network
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer	NCT05485766	Triple Negative... Triple Negative... Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation BRCA Mutation BRCA-Associated...	Pembrolizumab Paclitaxel Carboplatin Olaparib Definitive Surg...	18 Years -	Okayama University
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)	NCT04055038	Ovarian Cancer Ovarian Neoplas... Serous Adenocar... BRCA1 Mutation BRCA2 Mutation Chemotherapy	Platinum-Based ... Conventional ch...	18 Years - 70 Years	Blokhin's Russian Cancer Research Center
Prostate Cancer Genetic Risk Evaluation and Screening Study	NCT05129605	Prostatic Neopl... Prostate Cancer BRCA2 Mutation BRCA1 Mutation ATM Gene Mutati... MMR Mutation Lynch Syndrome Genetic Predisp...	Prostate cancer...	35 Years - 74 Years	Massachusetts General Hospital
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening	NCT04273542	Breast Cancer F... BRCA1 Mutation BRCA2 Mutation	liquid biopsy	18 Years -	Centre Jean Perrin
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC	NCT05358639	High Grade Sero... Triple Negative... Ovarian Cancer	Olaparib tablet Navitoclax	18 Years -	Sunnybrook Health Sciences Centre
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation	NCT01472783	Recurrent, Epit...	Veliparib	18 Years -	Vejle Hospital
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)	NCT04012229	Breast Cancer BRCA1 Mutation BRCA2 Mutation	BRCA mutation	18 Years -	Centre Hospitalier Universitaire de Besancon
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma	NCT05537844	Ovarian Cancer High Grade Sero... Carcinosarcoma,... Fallopian Tube ... Primary Periton... BRCA1 Mutation BRCA2 Mutation		16 Years -	Cancer Research UK, Glasgow
Genetic Education in BRCA Families	NCT03544983	BRCA1 Mutation BRCA2 Mutation	Web + Streamlin...	21 Years - 75 Years	Georgetown University
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)	NCT04012229	Breast Cancer BRCA1 Mutation BRCA2 Mutation	BRCA mutation	18 Years -	Centre Hospitalier Universitaire de Besancon
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors	NCT06177171	BRCA1 Mutation BRCA2 Mutation BRCA Mutation PALB2 Gene Muta... Checkpoint Kina... ATM Gene Mutati...	Olaparib ASTX727	18 Years -	University of California, San Francisco
Decision Support for BRCA Testing in Ethnically Diverse Women	NCT03470402	Breast Cancer BRCA1 Mutation BRCA2 Mutation Ovarian Cancer	RealRisks BNAV iNYP Standard Educat... High-Risk Messa...	21 Years - 75 Years	Columbia University
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC	NCT05358639	High Grade Sero... Triple Negative... Ovarian Cancer	Olaparib tablet Navitoclax	18 Years -	Sunnybrook Health Sciences Centre
Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing	NCT03475979	Breast Cancer BRCA1 Mutation BRCA2 Mutation Recurrent Breas... Metachronous Ne...		25 Years - 75 Years	Seoul National University Hospital
Health After eaRly Menopause Due to Oophorectomy	NCT03835793	Surgical Menopa... BRCA1 Mutation BRCA2 Mutation Cardiovascular ... Bone Mineral De... Cognitive Decli... Quality of Life Menopause Surgi...	CAC-score	55 Years -	The Netherlands Cancer Institute
Chemo-free BRCA-targeted Neoadjuvant Strategy	NCT05209529	TNBC - Triple-N... BRCA1 Mutation BRCA2 Mutation	olaparib Durvalumab	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors	NCT06380660	Solid Tumor, Ad... BRCA1 Mutation BRCA2 Mutation Ovarian Cancer Breast Cancer Prostate Cancer	ACE-86225106 ta...	18 Years -	Acerand Therapeutics Limited
Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance	NCT02974842	BRCA1 Mutation BRCA2 Mutation Atypia Suspicio...	MAKO 7	18 Years -	nVision Medical
3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women	NCT01409226	Breast Cancer BRCA1 Mutation BRCA2 Mutation	3.0-T MRI biopsy	18 Years - 70 Years	NYU Langone Health
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats	NCT01078662	Ovarian Breast Prostate Pancreatic Advanced Tumour...	olaparib	18 Years - 130 Years	AstraZeneca
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma	NCT05537844	Ovarian Cancer High Grade Sero... Carcinosarcoma,... Fallopian Tube ... Primary Periton... BRCA1 Mutation BRCA2 Mutation		16 Years -	Cancer Research UK, Glasgow
Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2	NCT05898009	Breast Cancer Genetic Disease BRCA2 Mutation	blood sample fo...	18 Years -	Centre Hospitalier Universitaire de la Réunion
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency	NCT02873975	Advanced Cancer...	LY2606368	18 Years -	Dana-Farber Cancer Institute
Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development	NCT00381927	Breast Cancer	Physician Couns...	18 Years -	Baystate Medical Center
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)	NCT04055038	Ovarian Cancer Ovarian Neoplas... Serous Adenocar... BRCA1 Mutation BRCA2 Mutation Chemotherapy	Platinum-Based ... Conventional ch...	18 Years - 70 Years	Blokhin's Russian Cancer Research Center
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation	NCT04858334	Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis...	18 Years -	National Cancer Institute (NCI)
Functional Analysis of BRCAness	NCT04780945	Ovarian Neoplas... Homologous Reco... BRCA1 Mutation BRCA2 Mutation	Functional RAD5... Olaparib Oral P...	18 Years -	Leiden University Medical Center
Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction	NCT01591746	Breast Cancer Pain, Postopera... BRCA1 Mutation BRCA2 Mutation Breast Diseases Neoplasms	Botulinum Toxin... Placebo	18 Years -	Mayo Clinic
The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a BRCA Gene Mutation.	NCT05097274	Prostate Cancer BRCA1 Mutation BRCA2 Mutation	MRI pelvis or C... Whole body bone... PET-CT imaging	18 Years -	Institute of Cancer Research, United Kingdom
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients	NCT05410951	Lobular Breast ... Lobular in Situ... BRCA1 Mutation BRCA2 Mutation	Illumina panel	18 Years - 99 Years	European Institute of Oncology
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening	NCT04273542	Breast Cancer F... BRCA1 Mutation BRCA2 Mutation	liquid biopsy	18 Years -	Centre Jean Perrin
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)	NCT04055038	Ovarian Cancer Ovarian Neoplas... Serous Adenocar... BRCA1 Mutation BRCA2 Mutation Chemotherapy	Platinum-Based ... Conventional ch...	18 Years - 70 Years	Blokhin's Russian Cancer Research Center
Chemo-free BRCA-targeted Neoadjuvant Strategy	NCT05209529	TNBC - Triple-N... BRCA1 Mutation BRCA2 Mutation	olaparib Durvalumab	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa	NCT01670500	Breast Cancer	Cisplatin Cyclophosphamid... Doxorubicin	18 Years -	Dana-Farber Cancer Institute
Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)	NCT04866992	Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Ductal Carcinom... Prognostic Stag... Prognostic Stag... BRCA1 Mutation BRCA2 Mutation		18 Years -	University of Texas Southwestern Medical Center
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients	NCT05410951	Lobular Breast ... Lobular in Situ... BRCA1 Mutation BRCA2 Mutation	Illumina panel	18 Years - 99 Years	European Institute of Oncology
Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction	NCT04108117	Postoperative C... Recurrence Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation Surgery Surgery--Compli...	Robotic nipple ...	-	Severance Hospital
Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer	NCT04190667	Epithelial Ovar... Chinese Homologous Reco... BRCA1 Mutation BRCA2 Mutation Prognosis	Genomic testing	18 Years -	Peking Union Medical College Hospital
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)	NCT04012229	Breast Cancer BRCA1 Mutation BRCA2 Mutation	BRCA mutation	18 Years -	Centre Hospitalier Universitaire de Besancon
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care	NCT02957981	Prostate Carcin... Breast Neoplasm Pancreatic Canc... BRCA1 Mutation BRCA2 Mutation	Web-based Couns... Standard Care	25 Years - 70 Years	Georgetown University
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care	NCT02957981	Prostate Carcin... Breast Neoplasm Pancreatic Canc... BRCA1 Mutation BRCA2 Mutation	Web-based Couns... Standard Care	25 Years - 70 Years	Georgetown University
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	NCT06395519	Advanced or Met... Breast Cancer Ovarian Cancer Prostate Cancer Epithelial Ovar... BRCA2 Mutation ER+ Breast Canc... Castrate Resist... BRCA1 Mutation BRCA Mutation Endometrial Can... Colorectal Canc... Gastric Cancer	ETX-19477	18 Years -	858 Therapeutics, Inc.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation	NCT04858334	Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis...	18 Years -	National Cancer Institute (NCI)
Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers	NCT03495609	hCG BRCA1 Mutation BRCA2 Mutation	Ovitrelle	18 Years - 30 Years	University Hospital, Ghent
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats	NCT01078662	Ovarian Breast Prostate Pancreatic Advanced Tumour...	olaparib	18 Years - 130 Years	AstraZeneca
Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction	NCT04108117	Postoperative C... Recurrence Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation Surgery Surgery--Compli...	Robotic nipple ...	-	Severance Hospital
Radical Fimbriectomy for Young BRCA Mutation Carriers	NCT01608074	BRCA1 Mutation BRCA2 Mutation Hereditary Brea...	Radical fimbrie... Histopathology ...	35 Years -	Centre Oscar Lambret
Dietary Intervention and BRCA Penetrance	NCT03066856	Dietary Modific... BRCA1 Mutation BRCA2 Mutation Breast Cancer	Dietary interve...	18 Years - 70 Years	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Web-based Family History Tool	NCT04890327	Gynecologic Can... Breast Cancer BRCA1 Mutation BRCA2 Mutation	Web-based famil...	18 Years - 100 Years	Weill Medical College of Cornell University
Liquid Biopsy Evaluation and Repository Development at Princess Margaret	NCT03702309	Cancer Breast Cancer Lung Cancer Colon Cancer Ovarian Cancer Melanoma Lymphoma Leukemia Mutation Lynch Syndrome Cowden Syndrome BRCA1 Mutation BRCA2 Mutation Uterine Cancer Myeloma Kidney Cancer Head and Neck C... Meningioma		18 Years -	University Health Network, Toronto
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC	NCT05358639	High Grade Sero... Triple Negative... Ovarian Cancer	Olaparib tablet Navitoclax	18 Years -	Sunnybrook Health Sciences Centre

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: